Experts have raised questions, however, about the added internal bleeding risks of rivaroxaban. Last year, a study warned newer blood thinners may result in a 48% higher rate of gastrointestinal bleeding than standard care.
New York, NY (PRWEB) August 05, 2014
The drug safety advocates at DrugNews.net are alerting patients who have taken the anticoagulant Xarelto of new information on the site. A recent report advises that complaints of internal bleeding linked to Xarelto have now surpassed those of competitors*.
DrugNews is a free resource providing the latest product recalls, safety alerts, research and litigation news for patients taking popular prescription drugs. Visitors can recognize potential dangers, see if others are experiencing similar side effects and decide if they need legal advice.
Xarelto is a popular blood thinning drug introduced in 2011 and sold by Bayer and Johnson & Johnson. It is prescribed to prevent strokes in patients with atrial fibrillation and to stop blood clots in those who have undergone surgery**.
Experts have raised questions, however, about the added internal bleeding risks of rivaroxaban. Last year, a study warned newer blood thinners may result in a 48% higher rate of gastrointestinal bleeding than standard care***.
Now, DrugNews has learned that the latest report from the Institute for Safe Medication Practices shows the number of internal bleeding cases linked to Xarelto has surpassed those of competitor drug Pradaxa as the number of prescriptions has grown to over 1 million per quarter*.
Lawyers are offering help to those injured. Anyone who suffered internal bleeding after taking Xarelto is encouraged to visit DrugNews.net or speak with a lawyer about their legal options. DrugNews only recommends lawyers who have already handled Xarelto lawsuits.
Visit http://www.DrugNews.net today for more information on the research, side effects and litigation news related to Xarelto and other drugs, or to speak with a lawyer.
*ISMP QuarterWatch, Anticoagulant Update, 5/7/14; ismp.org/QuarterWatch/pdfs/2013Q1.pdf
**FiercePharma, 10/2/13; fiercepharma.com/special-reports/xarelto-top-15-drug-launch-superstars
***American Gastroenterological Association, 3/7/13; gastrojournal.org/article/S0016-5085(13)00290-4/fulltext